埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究

doi:10.3969/j.issn.1006-7795.2022.02.021

首都医科大学学报 ›› 2022, Vol. 43 ›› Issue (2): 289-293.doi: 10.3969/j.issn.1006-7795.2022.02.021

埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究

姚舒洋¹, 李小雪¹, 王淳秀², 张毅^1*

1.首都医科大学宣武医院胸科, 北京 100053;
2.首都医科大学宣武医院循证医学中心, 北京 100053

收稿日期:2021-06-10 出版日期:2022-04-21 发布日期:2022-04-14
基金资助:
2019年吴阶平医学基金(19088-18)。

Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study

Yao Shuyang¹, Li Xiaoxue¹, Wang Chunxiu², Zhang Yi^1*

1. Department of Thoracic Surgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China;
2. Department of Evidence-based Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, China

Received:2021-06-10 Online:2022-04-21 Published:2022-04-14
Contact: *E-mail:steven9130@126.com
Supported by:
2019 Wu Jieping Medical Foundation (19088-18).

摘要/Abstract

摘要： 目的观察埃克替尼联合抗血管药物一线治疗表皮生长因子受体(epidermal growth factor receptor,EGFR)突变晚期肺腺癌的治疗效果和不良反应。方法选取首都医科大学宣武医院胸科2018年6月1日至2019年12月31日期间,37例EGFR突变晚期肺腺癌的患者。采用埃克替尼(125 mg/次,3 次/d)联合贝伐单抗(7.5 mg/kg,1次/3周);或埃克替尼(125 mg/次,3 次/d)联合安罗替尼(10~12 mg 1次/d,第1~14天),均21 d为1个周期,至疾病进展或出现严重的不良反应后终止。中位随访时间14.5(9.2~30.8)个月。结果本组患者中,62.2％(23/37)达到部分缓解,37.8％ (14/37) 达到疾病稳定。客观有效率为62.2％(23/37),疾病控制率为100％(37/37)。中位疾病无进展时间为17.9个月(95% CI:10.292~25.508)个月。1年生存率为83.8％,18个月生存率为81.1％。多因素Cox回归分析结果显示,肝转移和脑转移对患者的PFS有明显影响(P<0.05)。最常见不良反应为皮疹(43.2%, 16/37)和腹泻(21.6%, 8/37)。结论埃克替尼联合抗血管药物是一种有效且安全的一线治疗EGFR突变晚期肺腺癌的方案。

关键词: 肺腺癌, 表皮生长因子受体基因突变, 靶向治疗, 抗血管治疗

Abstract: Objective To assess the efficacy and safety of icotinib plus antiangiogenic agent for epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC). Methods From June 1, 2018 to December 31, 2019, in the Department of Thoracic Surgery of Xuanwu Hospital, Capital Medical University, we summarized the experience with icotinib plus antiangiogenic agent as the first-line treatment in 37 patients with advanced EGFR mutant lung adenocarcinoma. The patients received icotinib (125 mg, three times per day) combined with bevacizumab (7.5 mg/kg, every three weeks) or icotinib (125 mg, three times per day) combined with anlotinib (10-12 mg, daily, day 1-14) until disease progression or unacceptable toxicity. Each regimen was 21-day per cycle. The median follow-up was 14.5(9.2-30.8)months. Results In this study, 62.2％(23/37) achieved partial remissions and 37.8％ (14/37) achieved stable diseases. The objective response rate was 62.2％(23/37) and disease control rate was 100%. The median progression-free survival was 17.9(95%CI:10.292-25.508)months.One-year overall survival (OS) rate was 83.8％ and 18-month OS 81.1％.According to multivariate analysis, patients with liver metastasis or brain metastasis had significantly worse prognosis (P<0.05). Rash (43.2%, 16/37)and diarrhea(21.6%, 8/37) were predominant adverse events. Conclusion The combination of icotinib and antiangiogenic agent appears to be an efficient and well-tolerated regimen as first-line treatment for advanced EGFR mutant lung adenocarcinoma patients.

Key words: lung adenocarcinoma, epidermal growth factor receptor mutation, targeted therapy, antiangiogenic agent

中图分类号:

R587.1

姚舒洋, 李小雪, 王淳秀, 张毅. 埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究[J]. 首都医科大学学报, 2022, 43(2): 289-293.

Yao Shuyang, Li Xiaoxue, Wang Chunxiu, Zhang Yi. Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study[J]. Journal of Capital Medical University, 2022, 43(2): 289-293.

参考文献

[1] Herbst R S, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
[2] Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(3): 239-246.
[3] Wu Y L, Zhou C C, Hu C P, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(2): 213-222.
[4] Ichihara E, Hotta K, Nogami N, et al. Phase Ⅱ trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001[J]. J Thorac Oncol, 2015, 10(3): 486-491.
[5] Ichihara E, Ohashi K, Takigawa N, et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo[J]. Cancer Res, 2009, 69(12): 5091-5098.
[6] Ninomiya T, Nogami N, Kozuki T, et al. A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404[J]. Lung Cancer, 2018, 115: 103-108.
[7] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[8] Ettinger D S, Wood D E, Aisner D L, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021[J]. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
[9] 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. Ⅳ期原发性肺癌中国治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(1): 39-59.
[10] Shi Y K, Zhang L, Liu X Q, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial[J]. Lancet Oncol, 2013, 14(10): 953-961.
[11] Shi Y K, Wang L, Han B H, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study[J]. Ann Oncol, 2017, 28(10): 2443-2450.
[12] Xu L S, Qi Q, Zhang Y, et al. Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: a randomized controlled study[J]. Lung Cancer, 2019, 133: 23-31.
[13] Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20(5): 625-635.
[14] Nakagawa K, Garon E B, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(12): 1655-1669.
[15] Qu J, Wang Y N, Xu P, et al. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a Meta-analysis[J]. Oncotarget, 2017, 8(20): 33961-33971.

埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究

Icotinib plus antiangiogenic agent as the first-line treatment for advanced EGFR mutant lung adenocarcinoma: a single-center study

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	王丽, 武姣彦, 杨敏福. 初诊肺腺癌患者PET/CT显像的心肌代谢特征及影响左心室心肌代谢增高的因素分析[J]. 首都医科大学学报, 2021, 42(1): 1-7.
[2]	王明, 卜祥婷, 栾格, 王阳, 王成硕, 张罗. MALAT1在慢性鼻窦炎伴鼻息肉中的表达及对糖皮质激素治疗的反应性[J]. 首都医科大学学报, 2020, 41(2): 183-188.
[3]	冷菲, 李巍. 基于XGBoost对肺鳞癌和肺腺癌的分类预测[J]. 首都医科大学学报, 2019, 40(6): 889-893.
[4]	姚舒洋, 支修益. 非小细胞肺癌术后辅助EGFR-TKI的治疗进展[J]. 首都医科大学学报, 2016, 37(6): 773-776.
[5]	潘李珍. 新城疫弱病毒对人肺腺癌细胞系A549多细胞球体的作用[J]. 首都医科大学学报, 1997, 18(3): 209-213.